Global Site
Breadcrumb navigation
Pipeline
Indication
Preclinical
Phase I
Phase I/II
Phase II
Phase III
Partner
Personalized Neoantigen Vaccines
TG4050
Head & neck cancer
Ovarian cancer
NECVAX-NEO1
Basket solid tumors
Basket solid tumors
Triple negative breast cancer
Indication
Preclinical
Phase I
Phase II
Phase III
Partner
Universal Infectious Vaccines
Therapeutic vaccine
Hepatitis B
Prophylactic vaccine
Betacorona
Prophylactic vaccine
SFTS virus
Prophylactic vaccine
Dengue fever, Malaria, Ebola (and many others)
Prophylactic vaccine
Influenza
Personalized Neoantigen Vaccine for cancer treatment : TG4050
TG4050 is a virus-based therapeutic vaccine that incorporates a sequence of neoantigens (patient-specific mutations) selected by NEC‘s neoantigen prediction system into Transgene’s myvac®. It is designed to stimulate the immune system of patient in order to prime an innate and an adaptive response able to destroy tumor cells.
Details of clinical trial
Ovarian cancer (linked to clinicaltrials.gov)
Head and neck cancer(linked to clinicaltrials.gov)
Latest news
- Apr 10, 2024
-
Videos featuring TG4050's Phase I preliminary results
Webcast with Pr Ottensmeier (in English) - Conference call last November 23, 2021
Interview of the Transgene Team and Pr Ottensmeier
Relevant research paper
Personalized Neoantigen Vaccine : NECVAX-NEO1
NECVAX-NEO1 is an oral, Salmonella-based therapeutic vaccine that incorporates a sequence of neoantigens (patient-specific mutations) selected by the NEC Immune Profiler. It is designed to stimulate the immune system of patients in order to induce a T-cell response that is able to recognize and destroy tumor cells based on their own neoantigens. The NECVAX-NEO1 program initially co-developed with VAXIMM was acquired by NEC OncoImmunity following an asset acquisition deal.
Details of clinical trial
Various cancer (linked to clinicaltrials.gov)
Latest News